The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome

• Published in: Vaccine 2020-11, Vol.38 (47), p.7458-7463
• Main Authors: Miller, Elaine R., McNeil, Michael M., Moro, Pedro L., Duffy, Jonathan, Su, John R.
• Format: Article
• Language: English
• Subjects: Adverse Drug Reaction Reporting Systems; Adverse event; Anaphylaxis; Anaphylaxis - chemically induced; Anaphylaxis - epidemiology; Chicken pox; Collaboration; Combined vaccines; Disease control; Guillain-Barre syndrome; Guillain-Barre Syndrome - epidemiology; Human papillomavirus; Humans; Immunization; Influenza; Influenza A Virus, H1N1 Subtype; Influenza Vaccines - adverse effects; Intussusception; Measles; Medical records; Mumps; Pandemics; Passive surveillance; Polysaccharides; Public health; Rotavirus; Rubella; Safety; Sensitivity; Surveillance; Surveillance systems; Swine flu; United States - epidemiology; Vaccine; Vaccine Adverse Event Reporting System (VAERS); Vaccine safety; Vaccines; Varicella
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2020.09.072

•VAERS is a national passive post-licensure vaccine safety monitoring system.•Only two previous studies exist on the sensitivity of VAERS reporting.•We provide data on VAERS capture of anaphylaxis and Guillain-Barré syndrome. Underreporting is a limitation common to passive surveillance systems, including the Vaccine Adverse Event Reporting System (VAERS) that monitors the safety of U.S.-licensed vaccines. Nonetheless, previous reports demonstrate substantial case capture for clinically severe adverse events (AEs), including 47% of intussusception cases after rotavirus vaccine, and 68% of vaccine associated paralytic polio after oral polio vaccine. To determine the sensitivity of VAERS in capturing AE reports of anaphylaxis and Guillain-Barré syndrome (GBS) following vaccination and whether this is consistent with previous estimates for other severe AEs. We estimated VAERS reporting rates following vaccination for anaphylaxis and GBS. We used data from VAERS safety reviews as the numerator, and estimated incidence rates of anaphylaxis and GBS following vaccination from the Vaccine Safety Datalink (VSD) studies as the denominator. We defined reporting sensitivity as the VAERS reporting rate divided by the VSD incidence rate. Sensitivity was reported as either a single value, or a range if data were available from >1 study. VAERS sensitivity for capturing anaphylaxis after seven different vaccines ranged from 13 to 76%; sensitivity for capturing GBS after three different vaccines ranged from 12 to 64%. For anaphylaxis, VAERS captured 13–27% of cases after the pneumococcal polysaccharide vaccine, 13% of cases after influenza vaccine, 21% of cases after varicella vaccine, 24% of cases after both the live attenuated zoster and quadrivalent human papillomavirus (4vHPV) vaccines, 25% of cases after the combined measles, mumps and rubella (MMR) vaccine, and 76% of cases after the 2009 H1N1 inactivated pandemic influenza vaccine. For GBS, VAERS captured 12% of cases after the 2012–13 inactivated seasonal influenza vaccine, 15–55% of cases after the 2009 H1N1 inactivated pandemic influenza vaccine, and 64% of cases after 4vHPV vaccine. For anaphylaxis and GBS, VAERS sensitivity is comparable to previous estimates for detecting important AEs following vaccination.